¹⁹F MR Imaging of Dule Lung Cancer Models with Two Administration Methods of PFC Nanoparticles.

IF 2.5 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Molecular Imaging and Biology Pub Date : 2025-08-01 Epub Date: 2025-07-08 DOI:10.1007/s11307-025-02034-z

Fang Liu, Mengping Shao, Xiuan Xu

{"title":"19F MR Imaging of Dule Lung Cancer Models with Two Administration Methods of PFC Nanoparticles.","authors":"Fang Liu, Mengping Shao, Xiuan Xu","doi":"10.1007/s11307-025-02034-z","DOIUrl":null,"url":null,"abstract":"Background: Pulmonary delivery of agents to lung is an effective method for the diagnosis and therapy of lung cancer.Purpose: To demonstrate that pulmonary delivery of perfluorocarbon (PFC) nanoparticles for orthotopic lung tumor model is better than intravenous injection for subcutaneous tumor, and to confirm that the nanoparticles can be uptaked by tumor tissue which showed by 19F MR imaging and tissue staining.Methods: We detected the targeted ability of folate receptor (FR) targeted PFC nanoparticles with H460 cells in vitro. Subcutaneous and orthotopic lung cancer models were established. When the tumors could be detected by MR after two weeks, PFC nanoparticles were administrated intratracheally in orthotopic group and intravenously in subcutaneous group. 19F MR scanning was performed in mice models at before and different time points (4, 24, and 48 h) after delivery. Mice were euthanized after MR imaging, and tumor tissues were taken out, HE and fluorescent staining were performed respectively. In addition, orthotopic tumor tissue was obtained for transmission electron microscopy (TEM) examination.Results: The orthotopic tumor model showed a significant 19F MRI enhancement effect in the tumor region after PFC nanoparticles delivered intratracheally than subcutaneous model. As time went on, the accumulation of nanoparticles in the tumor area increased, and the 19F signal increased gradually. The 19F SNR in the tumor region of orthotopic group was significantly higher than that of subcutaneous group at 24 and 48 h after delivery (p < 0.001). Histological experiments showed that PFC nanoparticles accumulated in the tumor region especially in orthotopic group.Conclusion: Pulmonary delivery of PFC nanoparticles is a novel and effective method for orthotopic lung cancer xenograft model, and the PFC nanoparticles can be detected by 19F MR imaging in vivo.","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":"529-539"},"PeriodicalIF":2.5000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11307-025-02034-z","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Pulmonary delivery of agents to lung is an effective method for the diagnosis and therapy of lung cancer.

Purpose: To demonstrate that pulmonary delivery of perfluorocarbon (PFC) nanoparticles for orthotopic lung tumor model is better than intravenous injection for subcutaneous tumor, and to confirm that the nanoparticles can be uptaked by tumor tissue which showed by ¹⁹F MR imaging and tissue staining.

Methods: We detected the targeted ability of folate receptor (FR) targeted PFC nanoparticles with H460 cells in vitro. Subcutaneous and orthotopic lung cancer models were established. When the tumors could be detected by MR after two weeks, PFC nanoparticles were administrated intratracheally in orthotopic group and intravenously in subcutaneous group. ¹⁹F MR scanning was performed in mice models at before and different time points (4, 24, and 48 h) after delivery. Mice were euthanized after MR imaging, and tumor tissues were taken out, HE and fluorescent staining were performed respectively. In addition, orthotopic tumor tissue was obtained for transmission electron microscopy (TEM) examination.

Results: The orthotopic tumor model showed a significant ¹⁹F MRI enhancement effect in the tumor region after PFC nanoparticles delivered intratracheally than subcutaneous model. As time went on, the accumulation of nanoparticles in the tumor area increased, and the ¹⁹F signal increased gradually. The ¹⁹F SNR in the tumor region of orthotopic group was significantly higher than that of subcutaneous group at 24 and 48 h after delivery (p < 0.001). Histological experiments showed that PFC nanoparticles accumulated in the tumor region especially in orthotopic group.

Conclusion: Pulmonary delivery of PFC nanoparticles is a novel and effective method for orthotopic lung cancer xenograft model, and the PFC nanoparticles can be detected by ¹⁹F MR imaging in vivo.

查看原文本刊更多论文

两种PFC纳米颗粒给药方法对小结节肺癌模型的19F磁共振成像。

背景：肺内给药是诊断和治疗肺癌的有效方法。目的：研究全氟化碳纳米颗粒肺给药治疗原位肺肿瘤模型优于静脉给药治疗皮下肿瘤，并通过19F磁共振成像和组织染色证实PFC纳米颗粒可被肿瘤组织吸收。方法：体外检测叶酸受体（FR）靶向PFC纳米颗粒对H460细胞的靶向能力。建立皮下和原位肺癌模型。两周后，当MR检测到肿瘤时，原位组气管内给予PFC纳米颗粒，皮下组静脉给予PFC纳米颗粒。分别在分娩前和分娩后不同时间点（4、24、48 h）对小鼠模型进行19F磁共振扫描。mri成像后安乐死小鼠，取出肿瘤组织，分别进行HE和荧光染色。同时取原位肿瘤组织进行透射电镜（TEM）检查。结果：PFC纳米颗粒气管内给药后，原位肿瘤模型肿瘤区19F MRI增强效果明显优于皮下给药模型。随着时间的推移，肿瘤区域内纳米颗粒的积累增多，19F信号逐渐增强。移植后24和48 h，原位组肿瘤区19F信噪比明显高于皮下组(p)。结论：肺内给药PFC纳米颗粒是一种新颖有效的原位肺癌异种移植模型治疗方法，体内19F磁共振成像可检测到PFC纳米颗粒。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Imaging and Biology 医学-核医学

CiteScore

6.90

自引率

3.20%

发文量

审稿时长

3 months

期刊介绍： Molecular Imaging and Biology (MIB) invites original contributions (research articles, review articles, commentaries, etc.) on the utilization of molecular imaging (i.e., nuclear imaging, optical imaging, autoradiography and pathology, MRI, MPI, ultrasound imaging, radiomics/genomics etc.) to investigate questions related to biology and health. The objective of MIB is to provide a forum to the discovery of molecular mechanisms of disease through the use of imaging techniques. We aim to investigate the biological nature of disease in patients and establish new molecular imaging diagnostic and therapy procedures. Some areas that are covered are: Preclinical and clinical imaging of macromolecular targets (e.g., genes, receptors, enzymes) involved in significant biological processes. The design, characterization, and study of new molecular imaging probes and contrast agents for the functional interrogation of macromolecular targets. Development and evaluation of imaging systems including instrumentation, image reconstruction algorithms, image analysis, and display. Development of molecular assay approaches leading to quantification of the biological information obtained in molecular imaging. Study of in vivo animal models of disease for the development of new molecular diagnostics and therapeutics. Extension of in vitro and in vivo discoveries using disease models, into well designed clinical research investigations. Clinical molecular imaging involving clinical investigations, clinical trials and medical management or cost-effectiveness studies.